drugset
drugset / Trial / NCT04691115

Safety, Tolerability and Pharmacokinetics of AM1476 in Healthy Subjects

NCT04691115 ↗

Phase 1 Completed 97 enrolled AnaMar AB Covance · collab
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This is a First in Human (FIH), double-blind, randomised, placebo-controlled study designed to evaluate safety, tolerability and pharmacokinetics (PK) of single and multiple ascending oral doses of AM1476 in healthy subjects.

Timeline

Start
2020-12-16
Primary completion
2021-12-08
Completion
2021-12-08

Drugs

EvaluationDrugModalityDoseRoute
Subject AM1476 Unknown 1 mg Oral
Subject AM1476 Unknown 5 mg Oral
Subject AM1476 Unknown 25 mg Oral
Subject AM1476 Unknown 100 mg Oral
Subject AM1476 Unknown 125 mg Oral
Subject AM1476 Unknown 375 mg Oral
Subject AM1476 Unknown 500 mg Oral
Subject AM1476 Unknown 650 mg Oral
Subject AM1476 Unknown 950 mg Oral
Subject AM1476 Unknown 1500 mg Oral
Subject AM1476 Unknown 2400 mg Oral

Indications

No indication recorded.